LAGUNA HILLS, Calif.--(BUSINESS WIRE)--The American College for Advancement in Medicine, ACAM, today reaffirmed its commitment to the Trial to Assess Chelation Therapy (TACT) currently in progress by the National Institute of Health (NIH). The goal of the study is to test whether chelation therapy and/or high-dose vitamin therapy is effective for the treatment of heart disease. Chelation therapy is a process in which a synthetic or man-made amino acid called EDTA is delivered intravenously.
